JOHN MENDLEIN - 10 Mar 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Director
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
10 Mar 2022
Net transactions value
-$1,053,754
Form type
4
Filing time
11 Mar 2022, 15:58:59 UTC
Previous filing
29 Jul 2021
Next filing
06 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $51,446 +31,562 +20% $1.63 191,017 10 Mar 2022 Direct F1
transaction FATE Common Stock Sale $676,992 -19,493 -10% $34.73 171,524 10 Mar 2022 Direct F1, F2
transaction FATE Common Stock Sale $428,208 -12,069 -7% $35.48 159,455 10 Mar 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -31,562 -100% $0.000000* 0 10 Mar 2022 Common Stock 31,562 $1.63 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021.
F2 Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3.
F3 Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share.
F4 This option is fully vested.